|
Name |
(1R,2R,3R,6S,7S,10S,11S,12R,13S,16R,17S)-12-acetyloxy-1-hydroxy-6,10,13-trimethyl-16-propan-2-ylpentacyclo[9.7.0.02,7.03,7.013,17]octadecane-2-carboxylic acid
|
Molecular Formula | C27H42O5 | |
IUPAC Name* |
(1R,2R,3R,6S,7S,10S,11S,12R,13S,16R,17S)-12-acetyloxy-1-hydroxy-6,10,13-trimethyl-16-propan-2-ylpentacyclo[9.7.0.02,7.03,7.013,17]octadecane-2-carboxylic acid
|
|
SMILES |
C[C@H]1CC[C@]23[C@H](CC[C@H]2[C@@]3([C@@]4([C@@H]1[C@H]([C@]5(CC[C@@H]([C@@H]5C4)C(C)C)C)OC(=O)C)O)C(=O)O)C
|
|
InChI |
InChI=1S/C27H42O5/c1-14(2)18-10-11-24(6)19(18)13-26(31)21(22(24)32-17(5)28)15(3)9-12-25-16(4)7-8-20(25)27(25,26)23(29)30/h14-16,18-22,31H,7-13H2,1-6H3,(H,29,30)/t15-,16-,18+,19-,20+,21-,22+,24-,25-,26+,27+/m0/s1
|
|
InChIKey |
KFJVNPYEFKMGFB-NRCAVMDQSA-N
|
|
Synonyms |
Aspterpenacid A
|
|
CAS | NA | |
PubChem CID | 139591046 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 446.6 | ALogp: | 6.3 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.8 | Aromatic Rings: | 5 |
Heavy Atoms: | 32 | QED Weighted: | 0.576 |
Caco-2 Permeability: | -5.426 | MDCK Permeability: | 0.00002070 |
Pgp-inhibitor: | 0.58 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.51 |
30% Bioavailability (F30%): | 0.951 |
Blood-Brain-Barrier Penetration (BBB): | 0.639 | Plasma Protein Binding (PPB): | 95.51% |
Volume Distribution (VD): | 0.604 | Fu: | 2.91% |
CYP1A2-inhibitor: | 0.025 | CYP1A2-substrate: | 0.242 |
CYP2C19-inhibitor: | 0.013 | CYP2C19-substrate: | 0.769 |
CYP2C9-inhibitor: | 0.255 | CYP2C9-substrate: | 0.203 |
CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.088 |
CYP3A4-inhibitor: | 0.272 | CYP3A4-substrate: | 0.323 |
Clearance (CL): | 2.981 | Half-life (T1/2): | 0.343 |
hERG Blockers: | 0.275 | Human Hepatotoxicity (H-HT): | 0.266 |
Drug-inuced Liver Injury (DILI): | 0.641 | AMES Toxicity: | 0.024 |
Rat Oral Acute Toxicity: | 0.313 | Maximum Recommended Daily Dose: | 0.035 |
Skin Sensitization: | 0.919 | Carcinogencity: | 0.351 |
Eye Corrosion: | 0.598 | Eye Irritation: | 0.134 |
Respiratory Toxicity: | 0.965 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003939 | 0.783 | D0X7XG | 0.331 | ||||
ENC003725 | 0.404 | D09NNA | 0.295 | ||||
ENC001833 | 0.338 | D0G3SH | 0.294 | ||||
ENC004227 | 0.336 | D03ZTE | 0.294 | ||||
ENC006063 | 0.336 | D0M4WA | 0.292 | ||||
ENC002934 | 0.336 | D0AA0L | 0.288 | ||||
ENC001478 | 0.331 | D0Z8HG | 0.284 | ||||
ENC002216 | 0.326 | D00VZZ | 0.282 | ||||
ENC003219 | 0.324 | D0XX6Y | 0.281 | ||||
ENC003050 | 0.323 | D0R2KY | 0.281 |